NeuroimagingSystemic Therapies for Melanoma Brain Metastases A Primer for RadiologistsDodson, Cassidy BS*; Smith, Daniel A. MD*; Richards, Tyler J. MD†; Devita, Robert R. MD*; Hoimes, Christopher J. DO‡; Ramaiya, Nikhil H. MD*Author Information From the *Department of Radiology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH †Department of Radiology and Imaging Sciences, University of Utah Hospital, Salt Lake City, UT ‡Department of Medicine Division of Hematology and Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH. Correspondence to: Daniel A. Smith, MD, UH Cleveland Medical Center, 11100 Euclid Ave, Cleveland, OH 44106 (e-mail: Daniel.Smith3@UHhospitals.org). Received for publication December 27, 2019; accepted January 2, 2020. The authors declare no conflict of interest. Online date: March 26, 2020 Journal of Computer Assisted Tomography: May/June 2020 - Volume 44 - Issue 3 - p 346-355 doi: 10.1097/RCT.0000000000001006 Buy Metrics Abstract Objective The purpose of this article is to provide a primer for radiologists outlining the modern systemic therapies used in melanoma brain metastases, including tyrosine kinase inhibitors and immune checkpoint inhibitors. The role of radiologic treatment response evaluation will be discussed from the standpoint of both modern systemic therapies and more traditional treatments. Conclusion Understanding the role of systemic treatments in melanoma brain metastases is critical for oncologic imaging interpretation in this unique patient population. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.